Antileukotrienes in the treatment of asthma

Annals of Internal Medicine

Volumn 127, Issue 6, 1997, Pages 472-480

  O'Byrne, Paul M ^a   Israel, Elliot ^b   Drazen, Jeffrey M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LYN 171883; PEPTIDOLEUKOTRIENE; PLACEBO; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; COLD AIR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; EXERCISE INDUCED ASTHMA; HUMAN; HYPERVENTILATION; INHALATIONAL DRUG ADMINISTRATION; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030761053     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-6-199709150-00009     Document Type: Review

References (109)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol. 1938;94:187-91.
2. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol. 1940;30:121-45.
3. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol. 1960;151:416-35.
4. Drazen JM, Austen KF. Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2α on pulmonary mechanics in the guinea pig. J Clin Invest. 1974;53:1679-85.
5. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-75.
6. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological ettects. Science. 1987;237:1171-6.
7. Davidson FF, Dennis EA. Biological relevance of lipocortins and related proteins as inhibitors of phospholipase A2. Biochem Pharmacol. 1989;38: 3645-51.
8. Dennis EA. Modification of the arachidonic acid cascade through phospholipase A2 dependent mechanisms. Adv Prostaglandin Thromboxane Leukot Res. 1990;20:217-23.
9. Kaiser E, Chiba P, Zaky K. Phospholipases in biology and medicine. Clin Biochem. 1990;23:340-70.
10. Ferguson JE, Hanley MR. The role of phospholipases and phospholipid-derived signals in cell activation. Curr Opin Cell Biol. 1991;3:206-12.
11. Waite M. Phospholipases, enzymes that share a substrate class. Adv Exp Med Biol. 1990;279:430-7.
12. Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Proc Natl Acad Sci U S A. 1988;85:26-30.
13. Rouzer CA, Rands E, Kargman S, Jones RE, Register RB, Dixon RA. Characterization of cloned human leukocyte 5-lipoxygenase expressed in mammalian cells. J Biol Chem. 1988;263:10135-40.
14. Balcarek JM, Theisen TW, Cook MN, Varrichio A, Hwang SM, Strohsacker MW, et al. Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem. 1988;263:13937-41.
15. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, Mancini JA, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 1990;343:278-81.
16. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990;343:282-4.
17. Reid GK, Kargman S, Vickers PJ, Mancini JA, Leveille C, Ethier D, et al. Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J Biol Chem. 1990;265:19818-23.
18. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med. 1993;178: 1935-46.
19. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A. 1994;91:7563-7.
20. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun. 1980;96: 271-7.
21. 4 by human eosinophils. J Biol Chem. 1989;264:12885-9.
22. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980;77:3710-4.
23. Parker CW, Huber MM, Hoffman MK, Falkenhein SF. Characterization of the two major species of slow reacting substance from rat basophilic leukemic cells as glutathionyl thioesters of eicosatetraenoic acids oxygenated at the 5 position. Evidence that peroxy groups are present and important for spasmogenic activity. Prostaglandins. 1979;18:673-86.
24. Parker CW, Koch D, Huber MM, Falkenhein SF. Formation of the cysteinyl form of slow reacting substance (leukotriene E4) in human plasma. Biochem Biophys Res Commun. 1980;97:1038-46.
25. Schleimer RP, MacGlashan DW Jr, Peters SP, Pinckard RN, Adkinson NF Jr, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis. 1986;133:614-7.
26. 4. Proc Natl Acad Sci U S A. 1983;80:7626-30.
27. 4 from alveolar macrophages. Nature. 1982;297:329-31.
28. Schonfeld W, Schluter B, Hilger R, Konig W. Leukotriene generation and metabolism in isolated human lung macrophages. Immunology. 1988; 65:529-36.
29. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991; 256:929-37.
30. Ford-Hutchinson AW. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci. 1991;12:68-70.
31. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:283-5.
32. Wetmore LA, Gerard NP, Herron DK, Bollinger NG, Baker SR, Feldman HA, et al. Leukotriene receptor on U-937 cells: discriminatory responses to leukotrienes C4 and D4. Am J Physiol. 1991;261(2 Pt 1):L164-71.
33. Mong S, Wu HL, Scott MO, Lewis MA, Clark MA, Weichman BM, et al. Molecular heterogeneity of leukotriene receptors: correlation of smooth muscle contraction and radioligand binding in guinea-pig lung. J Pharmacol Exp Ther. 1985;234:316-25.
34. 4 receptor complex from guinea pig lung membranes. Mol Pharmacol. 1986;29:235-43.
35. 4 receptors in sheep tracheal smooth muscle. Mol Pharmacol. 1988;34:590-6.
36. 4 and antagonists of arachidonic acid metabolism and calcium entry on guinea pig tracheal muscle responsiveness. Prostaglandins Leukot Med. 1986;24:269-77.
37. 4 receptor. Trends Pharmacol Sci. 1989;10:103-7.
38. 4 receptor. Adv Prostaglandin Thromboxane Leukot Res 1990;20:127-37.
39. 4 receptors. Mol Pharmacol 1987;31:35-41.
40. 4. Mol Pharmacol. 1987;32:223-9.
41. 4 receptor antagonists. J Med Chem. 1991;34:2768-78.
42. 4 antagonist. J Pharmacol Exp Ther. 1985;233:148-57.
43. Hay DW, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG, et al. Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther. 1987;243:474-81.
44. Jones TR, Young R, Champion E, Charette L, Denis D, Ford-Hutchinson AW, et al. L-649,923 sodium (beta 5, gamma R)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-gamma-hydroxy-beta- methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can J Physiol Pharmacol. 1986;64:1068-75.
45. Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, et al. Pharmacology of L-660,711 (MK-571): a novel, potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989;67:17-27.
46. 4. J Pharmacol Exp Ther. 1991;259:751-9.
47. Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD. In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987;243:548-56.
48. Torphy TJ, Newton JF, Wasserman MA, Vickery-Clark L, Osborn RR, Bailey LS, et al. The bronchopulmonary pharmacology of SK&F 104353 in anaesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienes. J Pharmacol Exp Ther. 1989;249: 430-7.
49. 2 in vitro. J Pharmacol Exp Ther. 1984;228:128-32.
50. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991;337:1062-3.
51. Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992;146:358-63.
52. Impens N, Reiss TF, Teahan JA, Desmet M, Rossing TH, Shingo S, et al. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis. 1993;147(6 Pt 1):1442-6.
53. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993;119:1059-66.
54. Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis. 1984; 130:71-5.
55. Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre. Thorax. 1982;37:423-9.
56. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax. 1982;37:288-91.
57. Anderton RC, Cuff MT, Frith PA, Cockcroft DW, Morse JL, Jones NL, et al. Bronchial responsiveness to inhaled histamine and exercise. J Allergy Clin Immunol. 1979;63:315-20.
58. O'Byrne PM, Ryan G, Morris M, McCormack D, Jones NL, Morse JL, et al. Asthma induced by cold air and its relation to nonspecific bronchial responsiveness to methacholine. Am Rev Respir Dis. 1982;125:281-5.
59. Smith LJ, Greenberger PA, Patterson R, Krell RD, Bernstein PR. The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis. 1985;131: 368-72.
60. Manning PJ, O'Byrne PM. The effects of inhaled leukotriene D4 on histamine airway responsiveness in asthmatic subjects [Abstract]. Am Rev Respir Dis. 1992;145:287A.
61. Fischer AR, McFadden CA, Frantz R, Awni WM, Cohn J, Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness, in asthmatic subjects. Am J Respir Crit Care Med. 1995;152(4 Pt 1): 1203-7.
62. Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol. 1991;87:483-9.
63. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987; 136:379-83.
64. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis. 1989;139:806-17.
65. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH-2 like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326:298-304.
66. Sampson AP, Castling DP, Green CP, Price JF. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child. 1995; 73:221-5.
67. Diamant Z, Rensen EL, Callenbach PM, Veselic-Charvat MA, van der Veen H, Sterk PJ. Cell differentials in induced sputum after inhaled leukotriene D4 in subjects with mild asthma [Abstract]. Am J Respir Crit Care Med. 1996;153:A290.
68. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989-90.
69. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol. 1994;55:183-91.
70. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 1995;152: 897-905.
71. Anderson SD. Exercise-induced asthma. The state of the art. Am Rev Respir Dis. 1985;87S:191-5.
72. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990;323: 1736-9.
73. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204,219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992;145:746-9.
74. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis. 1993;147:1413-8.
75. Adelroth E, Inman MD, Summers E, Pace D, Modi M, O'Byrne PM. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997; 99:210-5.
76. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990;323:1740-4.
77. Anderson S, Seale JP, Ferris L, Schoeffel R, Lindsay DA. An evaluation of pharmacotherapy for exercise-induced asthma. J Allergy Clin Immunol. 1979;64:612-24.
78. Inman M, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 1996;153:65-9.
79. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994;88:363-8.
80. Ellis EF. Inhibition of exercise-induced asthma by theophylline. J Allergy Clin Immunol. 1984;73:690-2.
81. Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study. Eur Respir J. 1993;6:527-30.
82. Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis. 1992;145:1285-8.
83. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991;144:957-8.
84. Dahlen B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993;48:1018-26.
85. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-51.
86. Nasser SM, Bell GS, Foster S, Spruce KE, MacMillan R, Williams AJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49:749-56.
87. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993;48:1205-10.
88. Peat JK, Tovey E, Toelle BG, Haby MM, Gray EJ, Mahmic A, et al. House dust mite allergens. A major risk factor for childhood asthma in Australia. Am J Respir Crit Care Med. 1994;153:141-6.
89. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987;136:740-51.
90. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol. 1982;70:170-7.
91. Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989;1:584-8.
92. Manning PJ, Rokach J, Malo JL, Ethier D, Cartier A, Girard Y, et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990;86:211-20.
93. Mann JS, Robinson C, Sheridan AQ, Clement P, Bach MK, Holgate ST. Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorax. 1986;41: 746-52.
94. Bel EH, Timmers MC, Dijkman JH, Stahl EG, Sterk PJ. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol. 1990;85:1067-75.
95. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991;46: 184-9.
96. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991; 337:690-4.
97. Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992;90:193-201.
98. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993;147:839-44.
99. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995;95:42-51.
100. Hamilton AL, Watson R, Strong HA, Wylie G, O'Byrne PM. A 5-lipoxygenase activating protein antagonist, Bayx1005, attenuates both early and late phase allergen-induced bronchoconstriction in asthmatic subjects. Thorax. 1997;52:348-54.
101. Higgins DA, O'Byrne PM. Inhaled leukotriene D4 does not cause a late response in atopic subjects. Allergy Clin Immunol. 1987;79:141.
102. De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985;131:373-6.
103. Cloud ML, Enas GC, Kemp J, Platts-Mills T, Altman LC, Townley R, et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989;140:1336-9.
104. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994;150:618-23.
105. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996;98:528-34.
106. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996;275:931-6.
107. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996;98:859-71.
108. Sheffer AL, Bartal M, Bousquet J, Carrasco E, et al. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health, 1995;70-114.
109. Chapman KR, Friedman BS, Shingo S, Heyse J, Reiss T, Spector R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids [Abstract]. Am J Respir Crit Care Med. 1994; 149:A215.